Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 1037-1044

  Galsky, M D ^a   Camacho, L H ^b   Chiorean, E G ^c   Mulkerin, D ^d   Hong, D S ^e   Oh, W K ^a   Bajorin, D F ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Oncology Consultants   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Phase I; Renal impairment; Satraplatin; Solid tumors

Indexed keywords

CREATININE; SATRAPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COLON CANCER; CONSTIPATION; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EYE CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMOPTYSIS; HUMAN; HYPOTENSION; INFECTION; INTERMETHOD COMPARISON; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOLID TUMOR; SYNDROME DELINEATION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84859498740     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr358     Document Type: Article

References (17)

1. Kelland LR, Abel G, McKeage MJ et al. Preclinical antitumor evaluation of bisacetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 1993; 53: 2581-2586.
2. Twentyman PR, Wright KA, Mistry P et al. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992; 52: 5674-5680.
3. Mellish KJ, Barnard CF, Murrer BA, Kelland LR. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 1995; 62: 717-723.
4. Samimi G, Howell SB. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol 2006; 57: 781-788.
5. Beale P, Raynaud F, Hanwell J et al. Phase I study of oral JM216 given twice daily. Cancer Chemother Pharmacol 1998; 42: 142-148.
6. George CM, Haraf DJ, Mauer AM et al. A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. Invest New Drugs 2001; 19: 303-310.
7. Judson I, Cerny T, Epelbaum R et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 1997; 8: 604-606.
8. Raynaud FI, Boxall FE, Goddard P et al. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res 1996; 16: 1857-1862.
9. Raynaud FI, Mistry P, Donaghue A et al. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 1996; 38: 155-162.
10. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castraterefractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-5438.
11. Sternberg CN, Whelan P, Hetherington J et al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68: 2-9.
12. Fokkema E, de Vries EG, Meijer S, Groen HJ. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother Pharmacol 2000; 45: 89-92.
13. Dash A, Galsky MD, Vickers AJ et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107: 506-513.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
16. Ricart AD, Sarantopoulos J, Calvo E et al. Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study. Clin Cancer Res 2009; 15: 3866-3871.
17. Takimoto CH, Graham MA, Lockwood G et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 2007; 13: 4832-4839.